Abstract A034: Combination of ATR inhibitor (ATRi) and AKT inhibitor (AKTi) reduces tumor growth and prolongs survival in BRCA2 mutant (BRCA2m) PARP inhibitor (PARPi)-resistant high-grade serous ovarian cancer (HGSC)

Tzu-Ting Huang,Jayakumar R Nair,Jung-Min Lee,Chi-Ting Shih

doi:10.1158/1538-7445.ovarian23-a034

Abstract A034: Combination of ATR inhibitor (ATRi) and AKT inhibitor (AKTi) reduces tumor growth and prolongs survival in BRCA2 mutant (BRCA2m) PARP inhibitor (PARPi)-resistant high-grade serous ovarian cancer (HGSC)

Tzu-Ting Huang, Jayakumar R Nair + Show 2 more

https://doi.org/10.1158/1538-7445.ovarian23-a034

Copy DOI

Journal: Cancer Research

Publication Date: Mar 4, 2024

#Resistant High-grade Serous Ovarian Cancer #High-grade Serous Ovarian Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Abstract A034: Combination of ATR inhibitor (ATRi) and AKT inhibitor (AKTi) reduces tumor growth and prolongs survival in <i>BRCA2</i> mutant (BRCA2m) PARP inhibitor (PARPi)-resistant high-grade serous ovarian cancer (HGSC)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Cancer Research

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.